The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a significant substantial loss in body weight and enhance metabolic markers, p